Pimozide Tablets Suppliers & Bulk Manufacturers
Available Forms: Oral Tablets
Available Strengths: 1 mg, 2 mg, 4 mg
Reference Brands: Orap®(US & EU)
Category:
Antipsychotropic Drugs
Pimozide is a typical antipsychotic that primarily works by blocking dopamine D2 receptors in the brain, reducing excessive dopaminergic activity. It is mainly used to treat chronic schizophrenia and delusional disorders. Additionally, pimozide is FDA-approved for managing Tourette’s syndrome to suppress severe motor and vocal tics when other treatments fail.
Pimozide Tablets is available in Oral Tablets
and strengths such as 1 mg, 2 mg, 4 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pimozide Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pimozide Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pimozide tablets are FDA-approved in the United States for treating Tourette’s syndrome and are also indicated for chronic schizophrenia in select markets. In the EU, they are approved under strict guidelines for use in resistant schizophrenia and tic disorders. Both regions require compliance with GMP, pharmacovigilance, and detailed psychiatric safety data, especially concerning cardiac risks (QT prolongation). Registration demands a complete dossier including clinical data and labeling per FDA and EMA standards. To explore dossier-ready Pimozide tablets, APIs, and other available forms, visit Pharmatradz.com — your trusted B2B source for global pharmaceutical products.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing